Executive Profile

C. Boyd Clarke Venture Advisor, ProQuest Investments

Age	Total Calculated Compensation	This person is connected to 5 Board Members in 5 different organizations across 11 different industries. See Board Relationships
63	--

Background

Mr. C. Boyd Clarke serves as Industry Adviser of PolyTechnos Venture-Partners GmbH. Mr. Clarke serves as a Venture Advisor at ProQuest Investments. Mr. Clarke serves as a Senior Biotechnology and Pharmaceutical Executive with a significant record of accomplishment over a 30-year industry career. Mr. Clarke served as Chief Executive Officer at Neose Technologies Inc., from April 2002 to May 2006 and its Chairman of the Board from May 2003 to May 2006. He served as President ... at Neose Technologies Inc. from March 2002 to October 10, 2005. From December 1999 to March 2002, Mr. Clarke served as President and Chief Executive Officer at MedImmune Vaccines Inc. (formerly Aviron), which was acquired by MedImmune, and was also Chairman from January 2001 to March 2002. From 1998 to 1999, he served as Chief Executive Officer at MedImmune Oncology Inc. (formerly U.S. Bioscience Inc.) since March 1998 and also served as its President and Chief Operating Officer from 1996 to 1998. From 1977 to 1996, Mr. Clarke held a number of positions in sales and marketing and in general management at Merck & Co. Inc., including being the first President of Pasteur-Merieux MSD, and served as Vice President of Merck Vaccines. He serves as the Chairman of the Board at LigoCyte Pharmaceuticals, Inc. He served as Chairman of the Board at Mersana Therapeutics, Inc. Mr. Clarke served as Chairman of the Board of QLT Inc. since February 27, 2006 and as its Director since August 12, 2003. He serves as a Director of NovaDigm Therapeutics, Inc. Mr. Clarke serves as a Director of LigoCyte Pharmaceuticals, Inc. Mr. Clarke has been a Director of Rib-x Pharmaceuticals, Inc since July 2004. Mr. Clarke served as Director of Neose Technologies Inc. from March 2002 to May 2006. He served as a Director of MedImmune Oncology Inc., since September 1996. Mr. Clarke served as a Director of Acambis Inc. (formerly OraVax Inc.) since March 1997. He served as a Director of Biotechnology Industry Organization (BIO). He also serves on the Board of Trustees of the Textile Museum in Washington D.C. Mr. Clarke was a Doctoral candidate in European History at Concordia University Wisconsin. He holds an M.A. in European History from the University of Calgary and a B.S. in biochemistry.

Corporate Headquarters 2155 Analysis Drive Bozeman, Montana 59718 United States Phone: 406-585-2733 Fax: 406-585-2766 Board Members Memberships Executive Chairman LigoCyte Pharmaceuticals, Inc. Director Biotechnology Industry Organization Director Palkion Inc. 1996-N/A Former Chief Executive Officer, President and Director MedImmune Oncology Inc. 1997-N/A Former Director Sanofi Pasteur Biologics Co. 1999-N/A Former Chairman, Chief Executive Officer and President MedImmune Vaccines, Inc. 2002-N/A Former Director Neose Technologies Inc. 2003-N/A Former Chairman, Chairman of Corporate Governance Committee and Chairman of Nominating Committee QLT Inc. 2004-Present Director Rib-X Pharmaceuticals, Inc. 2007-N/A Former Chairman Mersana Therapeutics, Inc. 2010-Present Director NovaDigm Therapeutics, Inc. Education MA University Of Calgary BS University Of Calgary Doctorate Concordia University, Wisconsin Other Affiliations MedImmune Vaccines, Inc. Neose Technologies Inc. Sanofi Pasteur Biologics Co. MedImmune Oncology Inc. Merck & Co. Inc. QLT Inc. PolyTechnos Venture-Partners GmbH LigoCyte Pharmaceuticals, Inc. Rib-X Pharmaceuticals, Inc. Mersana Therapeutics, Inc. University Of Calgary Concordia University, Wisconsin Biotechnology Industry Organization NovaDigm Therapeutics, Inc. Palkion Inc.

Annual Compensation There is no Annual Compensation data available. Stocks Options There is no Stock Options data available. Total Compensation There is no Total Compensation data available.

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.